Abstract
ENZYMES PRODUCER GENencor International is the latest company to see opportunity in a projected shortfall in biopharmaceutical manufacturing capacity The firm, which is developing a health care portfolio to complement its traditional industrial enzymes business, intends to build a 22,000-sq-ft facility for the production of human therapeutic proteins. Debby Jo Blank, chiefbusiness officer for health care, says Genencor expects to be making clinical-trial quantities of products in its pipeline within 24 months. The first is a hepatitis vaccine, in development with .the five year-old vaccine firm Epimmune, that would be produced via microbial expression—the method used to make enzymes. The second product is expected to be one of several monoclonal antibodies in development with Seattle Genetics. It would be produced in mammalian cell culture. Genencor also intends to produce for third parties in need of capacity We hope to be able to form alliances with a small number of companies where we bring manufactur...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
